Navigation Links
Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytren's Contracture in E-poster at ASSH Meeting
Date:9/8/2011

nd cords, is highest in Caucasians, historically those of Northern European descent, with a global prevalence of three to six percent of the Caucasian population (1). Most cases of Dupuytren's contracture occur in patients older than 50 years (5).

The most frequently affected parts of the hand associated with Dupuytren's contracture are the joints called the Metacarpophalangeal Joint, or MP joint, which is the joint closest to the palm of the hand and the Proximal Interphalangeal Joint, or the PIP joint, which is the middle joint in the finger. The little finger and ring finger are most frequently involved. XIAFLEX is the only drug approved by the U.S. Food and Drug Administration for treatment of Dupuytren's contracture, which has historically been treated primarily by an open surgical procedure.

About the CORDLESS trial

The CORDLESS study is the largest prospective long term follow-up study of Dupuytren's contracture patients following a corrective procedure. This five-year observational study was designed to assess the durability of response following treatment with XIAFLEX, as well as long-term safety and progression of disease in patients from earlier Auxilium studies. In order to qualify for the XIAFLEX long-term extension study, patients must have participated in the phase III XIAFLEX clinical trials (CORD I, CORD II, JOINT I, JOINT II, or pharmacokinetic study) and received at least one injection of XIAFLEX. Recurrence in the long-term extension study was standardized and prospectively defined as (a) a joint contracture that was successfully treated (had previously achieved a reduction in contracture to five degrees or less at the Day 30 evaluation after the last injection of XIAFLEX) and that subsequently increases by at least 20 degrees compared to the reference value with a palpable cord present or, (b) a joint which underwent medical or surgical correction to treat contracture in that joint.

At three years, the nomi
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
2. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
3. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
4. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
5. Auxilium Pharmaceuticals to Present at the Stifel Nicolaus 2011 Healthcare Conference
6. Auxilium Pharmaceuticals, Inc. Announces Promotion of Dr. James P. Tursi to Chief Medical Officer
7. Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
8. Auxilium Pharmaceuticals Announces Results from Three Year CORDLESS Extension Study in Dupuytrens Contracture
9. Auxilium Pharmaceuticals to Present at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 36th Annual Health Care Conference
11. Auxilium Pharmaceuticals, Inc. Announces Launch of XIAPEX® in EU by Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... 5, 2011 Nektar Therapeutics (Nasdaq: NKTR ... patients in a Phase 2 clinical study evaluating single-agent ... of 33 women in the study with prior Doxil® ... response rate using either RECIST 1.0 criteria (response by ...
... CHICAGO, June 4, 2011 Genomic Health, Inc. (Nasdaq: ... studies being presented at the American Society of Clinical ... study confirming the performance of the Onco type ... predictor of recurrence risk in stage II colon cancer. ...
Cached Medicine Technology:NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 2NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 3NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 4NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 5NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 6NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 7NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil® 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 2Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 3Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 4Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 5Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 6Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 7Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 8Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting 9
(Date:7/11/2014)... The Williams Rejuva Center excited to ... patient’s unique treatment regime. Using the Vectra 3D ... trouble areas can be quickly created. The evaluation ... , Vectra 3D is a cutting-edge computer imaging system. ... a quick ‘snapshot’ of the skin to determine the ...
(Date:7/11/2014)... 11, 2014 Even the hot Texas sun ... Elementary School . The school had previously invested ... equipment from APCPLAY, but recently asked for an innovative ... , Godley Elementary School chose a Rectangular Shade from ... for children on their playground. The shade measures 24’W ...
(Date:7/11/2014)... July 11, 2014 Shu Cosmetic ... perineplasty for each qualifying patient undergoing a ... been performing laser vaginal rejuvenation, an advanced type ... The LVR procedure decreases the internal and external ... muscle tone, strength, and control, resulting in enhanced ...
(Date:7/11/2014)... ASHBURN PSYCHOLOGICAL AND PSYCHIATRIC SERVICES , On July 1st, Senate ... disability or autism to have a special code placed on ... law enforcement or first responders that they are dealing with ... a central Virginia mother, Ms. Pam Mines, who wanted to ... JP. During a news conference after the law passed, ...
(Date:7/10/2014)... (PRWEB) July 11, 2014 Karen Middleton, ... President and CEO of Planned Parenthood of the Rocky ... Senator Mark Udall and Representative Diana DeGette were in ... Court’s Hobby Lobby decision and keeping bosses out of ... representatives listened to the president today in Denver addressing ...
Breaking Medicine News(10 mins):Health News:Williams Rejuva Center Includes Innovative Computer Imaging 2Health News:Cool Fun Under the Texas Sun: Godley Elementary School Purchases Shade Structure from APCPLAY© 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 2Health News:Shu Cosmetic Surgery of Twin Cities Now Offers Complimentary Perineoplasty in Laser Vaginal Rejuvenation 3Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Naral Pro-Choice Colorado & Planned Parenthood Of The Rocky Mountains Statement On Udall & Degette Staying In Dc To Introduce Legislation 2
... ... for the Apple® iPhone. Module is the world’s first all-purpose iPhone case to ... ... February 24, 2010 -- Dacha Works LLC , the mobile computing accessories company, ...
... ... Company’s Future Growth , ... (PRWEB) March 17, 2010 -- Group Logic, a leading provider of desktop ... the company’s new chief executive officer (CEO). As a software industry veteran, Broderick ...
... Highly educated white men most likely to be tipplers, study ... to two-thirds (61 percent) of American adults consider themselves drinkers, ... likely to drink alcohol than women, and people with more ... of U.S. residents say they,ve abstained their whole lives. ...
... ... pharmacists with valuable information on topics such as operations management, economic analysis, reimbursement ... human resource strategies – vital competencies for pharmacy leaders and managers. , ... Sudbury, MA ...
... ... and high rates of asthma in Washington, DC. , ... Washington, DC (Vocus) March 17, 2010 -- Researchers ... asthma in metropolitan Washington, DC, are significantly more likely to have low levels of ...
... Worldwide Edition for his outstanding contributions and achievements in the field of healthcare. , ... , ... ... , ...
Cached Medicine News:Health News:Dacha Works Introduces Module- A Revolution In iPhone Case Design 2Health News:Group Logic, Inc. Appoints New CEO 2Health News:Group Logic, Inc. Appoints New CEO 3Health News:6 Out of 10 American Adults Drink 2Health News:New Book Reviews Core Competencies for Pharmacy Leaders 2Health News:New Book Reviews Core Competencies for Pharmacy Leaders 3Health News:New Book Reviews Core Competencies for Pharmacy Leaders 4Health News:Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids 2Health News:Study: Low Levels of Vitamin D Linked to Higher Rates of Asthma in African American Kids 3Health News:Dr. Mark Russell Recognized By Strathmore's Who's Who Worldwide Publication 2
... for catheter or instrument introduction. The ... be peeled away and removed. The ... instrument to be introduced should be ... the sheath. Supplied sterile in peel-open ...
Used for stenting the urethra after hypospadias or epispadias repair and to provide post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
... Used to provide ... or epispadias repair. The ... to partially close during ... urethra while maintaining urethral ...
... temporary internal drainage from ... the bladder. Supplied sterile ... for one-time use. CAUTION: ... C-Flex® and Sof-Flex® stents ...
Medicine Products: